Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 7Neoplasms 4Glioblastoma 4Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Rare Tumour 1Neuroectodermal Tumors 1Nervous System Diseases 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoadjuvant Therapy 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Locally Advanced Prostate Cancer 1Limited Stage Small Cell Lung Cancer 1Hereditary leiomyomatosis and renal cell cancer 1HER2-negative Breast Cancer 1Gliosarcoma 1Glioma 1For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment 1Esophageal Neoplasms 1Central Nervous System Neoplasms 1Carcinosarcoma 1

Interventions

sipuleucel-T 2enzalutamide 2pamiparib 1gallium 68 PSMA-11 1fluzoparib 1Vancomycin 1Prednisone 1Metronidazole 1Docetaxel 1Ciprofloxacin 1Amoxicillin 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-Resistant Prostate Cancer (mCRPC) × pamiparib × Clear all
NCT03712930 2021-11-17

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

BeiGene

Phase 2 Terminated
13 enrolled 11 charts
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡